Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders

Hultqvist, Malin LU ; Kutty Selva, Nandakumar LU ; Bjorklund, U and Holmdahl, Rikard LU (2009) In Annals of the Rheumatic Diseases 68(1). p.130-135
Abstract
Objectives: Autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) affect a relatively large portion of the population, leading to severe disability if left untreated. Even though pharmaceutics targeting the immune system have revolutionised the therapy of these diseases, there is still a need for novel, more effective therapeutic substances. One such substance is the new chemical entity 9-chloro-2,3 dimethyl-6-(N, N-dimthylamino-2-oxoethyl)-6H-indolo [2,3-b] quionoxaline, Rabeximod, currently being investigated for efficiency in treatment of human RA. In this study we aimed to evaluate Rabeximod as a treatment for autoimmune diseases, using animal models. Methods: In the present investigation we have evaluated... (More)
Objectives: Autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) affect a relatively large portion of the population, leading to severe disability if left untreated. Even though pharmaceutics targeting the immune system have revolutionised the therapy of these diseases, there is still a need for novel, more effective therapeutic substances. One such substance is the new chemical entity 9-chloro-2,3 dimethyl-6-(N, N-dimthylamino-2-oxoethyl)-6H-indolo [2,3-b] quionoxaline, Rabeximod, currently being investigated for efficiency in treatment of human RA. In this study we aimed to evaluate Rabeximod as a treatment for autoimmune diseases, using animal models. Methods: In the present investigation we have evaluated Rabeximod as a treatment for autoimmune diseases using mouse models of RA and MS, ie, collagen-induced arthritis, collagen antibody induced arthritis and experimental autoimmune encephalomyelitis. Results: Rabeximod efficiently prevented arthritis and encephalomyelitis in mice. In addition, this effect correlated to the timepoint when cells migrate into the joints. Conclusions: We conclude that Rabeximod reduces disease severity in animal models of autoimmunity and should be considered as a new therapeutic substance for MS and RA. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of the Rheumatic Diseases
volume
68
issue
1
pages
130 - 135
publisher
BMJ Publishing Group
external identifiers
  • wos:000261755800023
  • scopus:58349110928
  • pmid:18347009
ISSN
1468-2060
DOI
10.1136/ard.2007.085241
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Medical Inflammation Research (013212019)
id
84916284-213b-45fc-ae84-a9e6811782f2 (old id 1313839)
date added to LUP
2016-04-01 14:52:55
date last changed
2022-02-19 21:20:08
@article{84916284-213b-45fc-ae84-a9e6811782f2,
  abstract     = {{Objectives: Autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) affect a relatively large portion of the population, leading to severe disability if left untreated. Even though pharmaceutics targeting the immune system have revolutionised the therapy of these diseases, there is still a need for novel, more effective therapeutic substances. One such substance is the new chemical entity 9-chloro-2,3 dimethyl-6-(N, N-dimthylamino-2-oxoethyl)-6H-indolo [2,3-b] quionoxaline, Rabeximod, currently being investigated for efficiency in treatment of human RA. In this study we aimed to evaluate Rabeximod as a treatment for autoimmune diseases, using animal models. Methods: In the present investigation we have evaluated Rabeximod as a treatment for autoimmune diseases using mouse models of RA and MS, ie, collagen-induced arthritis, collagen antibody induced arthritis and experimental autoimmune encephalomyelitis. Results: Rabeximod efficiently prevented arthritis and encephalomyelitis in mice. In addition, this effect correlated to the timepoint when cells migrate into the joints. Conclusions: We conclude that Rabeximod reduces disease severity in animal models of autoimmunity and should be considered as a new therapeutic substance for MS and RA.}},
  author       = {{Hultqvist, Malin and Kutty Selva, Nandakumar and Bjorklund, U and Holmdahl, Rikard}},
  issn         = {{1468-2060}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{130--135}},
  publisher    = {{BMJ Publishing Group}},
  series       = {{Annals of the Rheumatic Diseases}},
  title        = {{The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders}},
  url          = {{http://dx.doi.org/10.1136/ard.2007.085241}},
  doi          = {{10.1136/ard.2007.085241}},
  volume       = {{68}},
  year         = {{2009}},
}